Top Suppliers:I want be here
Related CAS#:
83435-67-0 83435-66-9
108428-40-6 1700663-41-7
2711717-77-8 1115177-19-9
16154-78-2 15687-41-9
1049788-58-0 864374-00-5
1158522-08-7 940364-43-2
134104-43-1 131615-57-1
6906-52-1 930439-75-1
1018584-77-4 1375289-11-4
849349-65-1 127437-46-1

83435-67-0

83435-67-0 structure
83435-67-0 structure
  • Name: delapril hcl
  • Chemical Name: Delapril Hydrochloride
  • CAS Number: 83435-67-0
  • Molecular Formula: C26H33ClN2O5
  • Molecular Weight: 489.004
  • Catalog: API Circulatory system medication Antihypertensive drug
  • Create Date: 2018-07-05 10:13:32
  • Modify Date: 2024-01-04 20:56:12
  • Delapril is an angiotensin-converting enzyme (ACE) inhibitor for the treatment of cardiovascular diseases[1].
Name Delapril Hydrochloride
Synonyms N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-N-(2,3-dihydro-1H-inden-2-yl)glycine hydrochloride (1:1)
MFCD00884619
N-[(2S)-1-Ethoxy-1-oxo-4-phenyl-2-butanyl]-L-alanyl-N-(2,3-dihydro-1H-inden-2-yl)glycine hydrochloride (1:1)
delapril hcl
Glycine, N-[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-N-(2,3-dihydro-1H-inden-2-yl)-, hydrochloride (1:1)
Description Delapril is an angiotensin-converting enzyme (ACE) inhibitor for the treatment of cardiovascular diseases[1].
Related Catalog
Target

ACE[1]

In Vivo Delapril (3 mg/kg; administered orally for 2 weeks) exerts potent ACE inhibitory activity in spontaneously hypertensive rat (SHR) [1]. Delapril (1-10 mg/kg; orally) exerts a marked and long-lasting antihypertensive action in various experimental models of hypertension[1]. Animal Model: SHR[1] Dosage: 3 mg/kg Administration: Administered orally; 2 weeks Result: Exerted potent ACE inhibitory activity. Animal Model: 2-kidney, 1-clip hypertensive Rats, Dogs, and SHR[1] Dosage: 1-10 mg/kg Administration: Oral Result: Exerted a marked and long-lasting antihypertensive action.
References

[1]. Razzetti R, et al. Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensin-converting enzyme inhibitor. Am J Cardiol. 1995 Jun 16;75(18):7F-12F.
Boiling Point 659.7ºC at 760 mmHg
Melting Point 169ºC
Molecular Formula C26H33ClN2O5
Molecular Weight 489.004
Flash Point 352.7ºC
Exact Mass 488.207794
PSA 95.94000
LogP 3.80250

CHEMICAL IDENTIFICATION

RTECS NUMBER :
MB9668000
CHEMICAL NAME :
Glycine, N-(2,3-dihydro-1H-inden-2-yl)-N-(N-(1-(ethoxycarbonyl )-3-phenylpropyl)-L-a lanyl)-, monohydrochloride, (S)-
CAS REGISTRY NUMBER :
83435-67-0
LAST UPDATED :
199206
DATA ITEMS CITED :
8
MOLECULAR FORMULA :
C26-H32-N2-O5.Cl-H
MOLECULAR WEIGHT :
489.06

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
8260 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - body temperature decrease
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
208 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - body temperature decrease
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
5900 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
3120 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - body temperature decrease
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
164 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - body temperature decrease
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
2340 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - body temperature decrease
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
27300 mg/kg/13W-C
TOXIC EFFECTS :
Blood - changes in leukocyte (WBC) count
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),31,1987 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
8700 mg/kg
SEX/DURATION :
female 15-22 day(s) after conception lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987
83435-61-4 structure

83435-61-4

~92%

83435-67-0 structure

83435-67-0

Literature: Takeda Chemical Industries, Ltd. Patent: US4835302 A1, 1989 ;
1001015-87-7 structure

1001015-87-7

84793-24-8 structure

84793-24-8

~91%

83435-67-0 structure

83435-67-0

Literature: DIPHARMA FRANCIS s.r.l. Patent: US2008/15383 A1, 2008 ; Location in patent: Page/Page column 3 ;
83435-62-5 structure

83435-62-5

~71%

83435-67-0 structure

83435-67-0

Literature: Miyake; Itoh; Oka Chemical and Pharmaceutical Bulletin, 1986 , vol. 34, # 7 p. 2852 - 2858
64920-29-2 structure

64920-29-2

~%

83435-67-0 structure

83435-67-0

Literature: Chemical and Pharmaceutical Bulletin, , vol. 34, # 7 p. 2852 - 2858
83402-63-5 structure

83402-63-5

~%

83435-67-0 structure

83435-67-0

Literature: Chemical and Pharmaceutical Bulletin, , vol. 34, # 7 p. 2852 - 2858
80828-38-2 structure

80828-38-2

~%

83435-67-0 structure

83435-67-0

Literature: Chemical and Pharmaceutical Bulletin, , vol. 34, # 7 p. 2852 - 2858
80828-26-8 structure

80828-26-8

~%

83435-67-0 structure

83435-67-0

Literature: Chemical and Pharmaceutical Bulletin, , vol. 34, # 7 p. 2852 - 2858
615-13-4 structure

615-13-4

~%

83435-67-0 structure

83435-67-0

Literature: Chemical and Pharmaceutical Bulletin, , vol. 34, # 7 p. 2852 - 2858

Chemsrc provides CAS#:83435-67-0 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 83435-67-0 | Chemsrc address: https://www.chemsrc.com/en/baike/829514.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved